WW International, Inc. Announces Fourth Quarter and Full Year 2023 Results
Financial Statement
WW International, Inc. Announces Fourth Quarter and Full Year 2023 Results
Fourth Quarter 2023
End of Period Subscribers of 3.8 million, including 67 thousand End of Period Clinical Subscribers
Revenues of $206.0 million
Gross margin of 60.6%; excluding the net impact of restructuring charges, adjusted gross margin of 61.4%
Operating Loss of $6.0 million; excluding the net impact of restructuring charges and non-cash intangible impairment charges, adjusted operating income of $21.3 million
Full Year Fiscal 2023
Revenues of $889.6 million
Gross margin of 59.5%; excluding the net impact of restructuring charges, adjusted gross margin of 61.9%
Operating Income of $22.3 million; excluding the net impact of restructuring charges, acquisition transaction costs, and non-cash intangible impairment charges, adjusted operating income of $89.5 million
Company Provides Full Year Fiscal 2024 Guidance
NEW YORK, Feb. 28, 2024 (GLOBE NEWSWIRE) -- WW International, Inc. (NASDAQ: WW) (“WeightWatchers,” “WW,” or the “Company”) today announced its results for the fourth quarter and full year fiscal 2023.
“2023 was a pivotal year as we began transforming our business for the future. We returned WeightWatchers to year end subscriber growth – for the first time in 3 years - up 7% year-over-year,” said Sima Sistani, the Company’s CEO. “We are on track to deliver growth in total subscribers in 2024, expecting to end the year with subscribers in the range of 3.8 million to 4.0 million, including between 140 thousand and 160 thousand subscribers to our new WeightWatchers Clinic.”
“WeightWatchers is creating the category of Weight Health, and to do so requires us to go further in the transformation and expand our offerings to deliver the support, services, and treatments that many need to advance their weight loss journeys. We are making intentional choices to prioritize these initiatives that we believe will have the greatest benefit for the long-term health of our business,” continued Sistani.
“We executed against our 2023 objectives with a return to sign up and subscriber growth, record adjusted gross margin, and improved cost structure,” said Heather Stark, the Company’s CFO. “We anticipate returning to year-over-year growth in subscription revenues in the second half of 2024, and we are committed to improving margins and driving operating income growth.”
Q4 2023 Consolidated Results
% Change % Change
Adjusted for
Constant
Currency(1) Three Months Ended December 30, December 31, 2023 2022(7) (in millions except percentages and per share amounts)
Subscription Revenues, net$196.1 $200.9 (2.4%) (3.6%) Product Sales and Other, net9.9 22.0 (55.1%) (55.3%) Revenues, net$206.0 $222.9 (7.6%) (8.7%) Gross Profit$124.9 $126.0 (0.9%) (2.4%) Non-GAAP Adjustments(1) Net Restructuring Charges(2)1.5 3.1 Adjusted Gross Profit(1)$126.4 $129.1 (2.1%) (3.6%) Operating Loss($6.0) ($51.8) (88.4%) (86.7%) Non-GAAP Adjustments(1) Franchise Rights Acquired and Goodwill Impairments3.6 57.6 Net Restructuring Charges(2)23.6 17.4 Adjusted Operating Income(1)$21.3 $23.1 (8.1%) (12.4%) Net Loss($88.1) ($35.8) 100.0%* 100.0%* EPS($1.11) ($0.51) 100.0%* 100.0%*
Total Paid Weeks 50.4 47.3 6.5% N/A Digital(3) Paid Weeks41.0 37.8 8.6% N/A Workshops + Digital(4) Paid Weeks8.7 9.6 (9.2%) N/A Clinical(5) Paid Weeks0.7 - N/A N/A End of Period Subscribers(6) 3.8 3.5 7.1% N/A Digital Subscribers3.1 2.8 8.6% N/A Workshops + Digital Subscribers0.7 0.7 (8.3%) N/A Clinical Subscribers0.1 - N/A N/A ___________________________________
Note: Totals may not sum due to rounding.
*Note: Percentage in excess of 100.0% and not meaningful.
See “Reconciliation of Non-GAAP Financial Measures” attached to this release for further detail on adjustments to GAAP financial measures.
See “Reconciliation of Non-GAAP Financial Measures” attached to this release for further detail on the Company’s previously disclosed 2023, 2022, 2021, and 2020 restructuring plans, and the reversal of certain of the charges associated therewith.
“Digital” refers to providing subscriptions to the Company’s digital product offerings, which formerly included Digital 360 (as applicable).
“Workshops + Digital” refers to providing unlimited access to the Company’s workshops combined with the Company’s digital subscription product offerings to commitment plan subscribers, including former Digital 360 members (as applicable). It also formerly included the provision of access to workshops for members who did not subscribe to commitment plans, which included the Company’s “pay-as-you-go” members.
“Clinical” refers to providing subscriptions to the Company’s clinical product offerings provided by WeightWatchers Clinic (formally referred to as Sequence).
“Subscribers” refers to Digital subscribers, Workshops + Digital subscribers, and Clinical subscribers who participate in recurring bill programs in Company-owned operations.
Certain amounts have been revised for the three months ended December 31, 2022 to correct immaterial misstatements related to certain income tax and other matters, which will be more fully described in the Company's Form 10-K filing for the fiscal year ended December 30, 2023.
Q4 2023 Business and Financial Highlights
End of Period Subscribers in Q4 2023 were up 7.1% versus the prior year period, driven by the Digital business and the inclusion of 67 thousand Clinical Subscribers. Q4 2023 End of Period Digital Subscribers increased 8.6% versus the prior year period. Q4 2023 End of Period Workshops + Digital Subscribers decreased 8.3% versus the prior year period.
Total Paid Weeks in Q4 2023 were up 6.5% versus the prior year period, driven by the Digital business and the inclusion of 719 thousand Clinical Paid Weeks. Q4 2023 Digital Paid Weeks increased 8.6% versus the prior year period. Q4 2023 Workshops + Digital Paid Weeks decreased 9.2% versus the prior year period.
Revenues in Q4 2023 were $206.0 million. On a constant currency basis, Q4 2023 revenues decreased 8.7% versus the prior year period.
Subscription Revenues in Q4 2023 were $196.1 million. On a constant currency basis, these revenues decreased 3.6% versus the prior year period. Subscription Revenues included $13.0 million of Clinical Subscription Revenues.
Product Sales and Other in Q4 2023 were $9.9 million. On a constant currency basis, these revenues decreased 55.3% versus the prior year period driven by the wind down of the consumer products business.
Gross Profit in Q4 2023 was $124.9 million, compared to $126.0 million in the prior year period. Adjusted gross profit in Q4 2023, which excluded the net impact of $1.5 million of restructuring charges, was $126.4 million. Adjusted gross profit in Q4 2022, which excluded the net impact of $3.1 million of restructuring charges, was $129.1 million.
Gross Margin in Q4 2023 was 60.6%, as compared to 56.5% in the prior year period. Adjusted gross margin in Q4 2023 was 61.4%, up from an adjusted gross margin of 57.9% in the prior year period, primarily driven by actions to reduce the fixed cost base within the Workshops + Digital business.
Non-Cash Intangible Impairment Charges: During Q4 2023, the Company fully impaired the goodwill and franchise rights acquired balances for past franchise acquisitions in the Republic of Ireland and Northern Ireland, resulting in total charges of $3.6 million.
Operating Loss in Q4 2023 was $6.0 million, compared to operating loss of $51.8 million in the prior year period. Adjusted operating income in Q4 2023, which excluded the net impact of $23.6 million of restructuring charges and non-cash intangible impairment charges of $3.6 million, was $21.3 million. Adjusted operating income in Q4 2022, which excluded the impact of non-cash intangible impairment charges totaling $57.6 million and the net impact of $17.4 million of restructuring charges, was $23.1 million.
Income Tax Expense in Q4 2023 was $57.6 million, which reflected an increase in the valuation allowance to offset all U.S. deferred tax assets due to the uncertainty of realizing future tax benefits of the assets. In the prior year period, income tax was a benefit of $36.7 million.
Net Loss in Q4 2023 was $88.1 million compared to net loss of $35.8 million in the prior year period.
Diluted Net Loss per share in Q4 2023 was $1.11 compared to diluted net loss per share of $0.51 in the prior year period.
Certain items affect year-over-year comparability.
Q4 2023 diluted net loss per share incorporated the net negative impact of $1.05 per diluted share in the aggregate due to the following items:
$0.78 per diluted share negative tax impact due to an increase in the valuation allowance to offset all U.S. deferred tax assets due to the uncertainty of realizing future tax benefits of the assets.
$0.22 per diluted share net negative impact of restructuring charges.
$0.05 per diluted share negative impact of non-cash intangible impairment charges for franchise rights acquired and goodwill.
Q4 2022 diluted net loss per share incorporated the negative impact of $0.52 per diluted share in the aggregate due to the following items:
$0.63 per diluted share negative impact of non-cash intangible impairment charges for franchise rights acquired and goodwill.
$0.18 per diluted share net negative impact of restructuring charges.
$0.68 per diluted share positive tax impact of a legal entity restructuring that resulted in a reversal of certain deferred tax liabilities.
$0.38 per diluted share negative tax impact of establishing a valuation allowance to offset certain deferred tax assets due to the uncertainty of realizing future tax benefits from interest expense carryforwards.
Full Year Fiscal 2023 Consolidated Results
% Change % Change
Adjusted for
Constant
Currency(1) Twelve Months Ended December 30, December 31, 2023 2022(7) (in millions except percentages and per share amounts)
Subscription Revenues, net$ 822.8 $ 919.1 (10.5%) (10.6%) Product Sales and Other, net 66.8 120.8 (44.7%) (44.3%) Revenues, net$889.6 $1,039.8 (14.5%) (14.5%) Gross Profit$529.3 $621.4 (14.8%) (15.0%) Non-GAAP Adjustments(1) Net Restructuring Charges(2)21.2 7.0 Adjusted Gross Profit(1)$550.5 $628.4 (12.4%) (12.6%) Operating Income (Loss)$22.3 ($284.0) 100.0%* 100.0%* Non-GAAP Adjustments(1) Franchise Rights Acquired and Goodwill Impairments3.6 396.7 Net Restructuring Charges(2)54.9 39.7 Acquisition Transaction Costs8.6 - Adjusted Operating Income(1)$89.5 $152.5 (41.3%) (42.7%) Net Loss($112.3) ($256.9) (56.3%) (55.8%) EPS($1.46) ($ 3.65) (59.9%) (59.4%)
Total Paid Weeks 207.2 215.7 (3.9%) N/A Digital(3) Paid Weeks167.9 175.8 (4.5%) N/A Workshops + Digital(4) Paid Weeks37.7 39.9 (5.3%) N/A Clinical(5) Paid Weeks1.6 - N/A N/A End of Period Subscribers(6) 3.8 3.5 7.1% N/A Digital Subscribers3.1 2.8 8.6% N/A Workshops + Digital Subscribers 0.7 0.7 (8.3%) N/A Clinical Subscribers0.1 - N/A N/A ___________________________________
Note: Totals may not sum due to rounding.
*Note: Percentage in excess of 100.0% and not meaningful.
See “Reconciliation of Non-GAAP Financial Measures” attached to this release for further detail on adjustments to GAAP financial measures.
See “Reconciliation of Non-GAAP Financial Measures” attached to this release for further detail on the Company’s previously disclosed 2023, 2022, 2021, and 2020 restructuring plans, and the reversal of certain of the charges associated therewith.
“Digital” refers to providing subscriptions to the Company’s digital product offerings, which formerly included Digital 360 (as applicable).
“Workshops + Digital” refers to providing unlimited access to the Company’s workshops combined with the Company’s digital subscription product offerings to commitment plan subscribers, including former Digital 360 members (as applicable). It also formerly included the provision of access to workshops for members who did not subscribe to commitment plans, which included the Company’s “pay-as-you-go” members.
“Clinical” refers to providing subscriptions to the Company’s clinical product offerings provided by WeightWatchers Clinic (formally referred to as Sequence).
“Subscribers” refers to Digital subscribers, Workshops + Digital subscribers, and Clinical subscribers who participate in recurring bill programs in Company-owned operations.
Certain amounts have been revised for the twelve months ended December 31, 2022 to correct immaterial misstatements related to certain income tax and other matters, which will be more fully described in the Company's Form 10-K filing for the fiscal year ended December 30, 2023.
Full Year Fiscal 2023 Business and Financial Highlights
Total Paid Weeks in fiscal 2023 were down 3.9% versus the prior year, driven by declines in the Digital and Workshops + Digital businesses. Fiscal 2023 Digital Paid Weeks decreased 4.5% versus the prior year. Fiscal 2023 Workshops + Digital Paid Weeks decreased 5.3% versus the prior year. Fiscal 2023 included 1.6 million Clinical Paid Weeks.
Revenues in fiscal 2023 were $889.6 million. On a constant currency basis, fiscal 2023 revenues decreased 14.5% versus the prior year.
Subscription Revenues in fiscal 2023 were $822.8 million. On a constant currency basis, these revenues decreased 10.6% versus the prior year. Subscription Revenues included $30.5 million of Clinical Subscription Revenues.
Product Sales and Other in fiscal 2023 were $66.8 million. On a constant currency basis, these revenues decreased 44.3% versus the prior year driven by the wind down of the consumer products business.
Gross Profit in fiscal 2023 was $529.3 million, compared to $621.4 million in the prior year. Adjusted gross profit in fiscal 2023, which excluded the net impact of $21.2 million of restructuring charges, was $550.5 million. Adjusted gross profit in fiscal 2022, which excluded the net impact of $7.0 million of restructuring charges, was $628.4 million.
Gross Margin in fiscal 2023 was 59.5%, as compared to 59.8% in the prior year. Adjusted gross margin in fiscal 2023 was 61.9%, up from an adjusted gross margin of 60.4% in the prior year, primarily driven by actions to reduce the fixed cost base within the Workshops + Digital business.
Operating Income in fiscal 2023 was $22.3 million, compared to operating loss of $284.0 million in the prior year. Adjusted operating income in fiscal 2023, which excluded the net impact of $54.9 million of restructuring charges, $8.6 million of acquisition transaction costs, and $3.6 million of non-cash intangible impairment charges was $89.5 million. Adjusted operating income in fiscal 2022, which excluded the impact of non-cash intangible impairment charges totaling $396.7 million and the net impact of $39.7 million of restructuring charges, was $152.5 million.
Income Tax Expense in fiscal 2023 was $38.6 million, which reflected an increase in the valuation allowance to offset all U.S. deferred tax assets due to the uncertainty of realizing future tax benefits of the assets. In the prior year, income tax was a benefit of $109.9 million.
Net Loss in fiscal 2023 was $112.3 million compared to net loss of $256.9 million in the prior year.
Diluted Net Loss per share in fiscal 2023 was $1.46 compared to diluted net loss per share of $3.65 in the prior year.
Certain items affect year-over-year comparability.
Fiscal 2023 diluted net loss per share incorporated the net negative impact of $1.34 per diluted share in the aggregate due to the following items:
$0.66 per diluted share negative tax impact due to an increase in the valuation allowance to offset all U.S. deferred tax assets due to the uncertainty of realizing future tax benefits of the assets.
$0.54 per diluted share net negative impact of restructuring charges.
$0.10 per diluted share negative impact from acquisition transaction costs.
$0.05 per diluted share negative impact of non-cash intangible impairment charges for franchise rights acquired and goodwill.
Fiscal 2022 diluted net loss per share incorporated the negative impact of $4.38 per diluted share in the aggregate due to the following items:
$4.28 per diluted share negative impact of non-cash intangible impairment charges for franchise rights acquired and goodwill.
$0.42 per diluted share net negative impact of restructuring charges.
$0.69 per diluted share positive tax impact of a legal entity restructuring that resulted in a reversal of certain deferred tax liabilities.
$0.39 per diluted share negative tax impact of establishing a valuation allowance to offset certain deferred tax assets due to the uncertainty of realizing future tax benefits from interest expense carryforwards.
$0.03 per diluted share tax benefit due to out-of-period income tax adjustments.
Other Items
Cash balance as of December 30, 2023 was $109.4 million. On that same date, the Company had no outstanding borrowings under its revolving credit facility.
2023 Restructuring Plan: In connection with the previously announced 2023 restructuring plan, the Company recorded aggregate restructuring charges of $23.1 million in Q4 2023. This is higher than the previously disclosed estimate of up to $10.0 million as the Company continued to centralize and streamline its organization resulting in additional charges.
Reporting Segment Update: As a result of the continued evolution of the Company’s centralized organizational structure in fiscal 2023, and management’s 2024 strategic planning process, the Company’s reporting segments changed commencing with the first day of fiscal 2024 to one segment based on total revenue. This segment reflects the Company’s global management of the business and will present results on a global basis. The Company’s reporting segments in fiscal 2023 were North America and International.
Full Year Fiscal 2024 Guidance
The Company is providing the following full year fiscal 2024 guidance:
Revenues are expected to be in the range of $830.0 million to $860.0 million, reflecting a $55 million year-over-year headwind from the strategic decision to wind down the Company’s low-margin consumer products business.
Operating Income is expected to be in the range of $100.0 million to $110.0 million. Changes to modernize the Company’s technology organization required the Company to update its capitalized labor rate expectations. Based on these updated expectations, an estimated $9.0 million of expenses that were previously expected to be capitalized will now be reflected on the income statement in 2024. This shift in operating methodology does not impact cash.
Fourth Quarter and Full Year 2023 Conference Call and Webcast
The Company has scheduled a conference call today at 5:00 p.m. ET. During the conference call, Sima Sistani, Chief Executive Officer, and Heather Stark, Chief Financial Officer, will discuss the fourth quarter and full year fiscal 2023 results and answer questions from the investment community.
The live webcast of the conference call will be available on the Company’s corporate website, corporate.ww.com, under Events and Presentations. Supplemental investor materials will also be available in the same location prior to the start of the webcast. A replay of the webcast will be available on this site for approximately 90 days.
Statement regarding Non-GAAP Financial Measures
The following provides information regarding non-GAAP financial measures used in this earnings release and today’s scheduled conference call:
To supplement the Company's consolidated results presented in accordance with accounting principles generally accepted in the United States (“GAAP”), the Company has disclosed non-GAAP financial measures of operating results that exclude or adjust certain items. Gross profit, gross margin, operating income (loss), operating income (loss) margin, and selling, general and administrative expenses are discussed both as reported (on a GAAP basis) and as adjusted (on a non-GAAP basis), as applicable, with respect to (i) the fourth quarter of fiscal 2023 to exclude (a) the net impact of (w) charges associated with the Company's previously disclosed 2023 restructuring plan (the “2023 plan”) and (x) charges associated with the Company's previously disclosed 2022 restructuring plan (the “2022 plan”), and (b) the impact of the impairment charges for the Company's goodwill related to its Republic of Ireland and Northern Ireland reporting units and the impairment charge for the Company's franchise rights acquired related to its Northern Ireland unit of account; (ii) the full year of fiscal 2023 to exclude (a) the net impact of (w) charges associated with the Company's 2023 plan, (x) charges associated with the Company's 2022 plan or the reversal of certain of the charges associated with the 2022 plan, as applicable, (y) charges associated with the Company's previously disclosed 2021 organizational restructuring plan (the “2021 plan”) or the reversal of certain of the charges associated with the 2021 plan, as applicable, and (z) the reversal of certain of the charges associated with the Company's previously disclosed 2020 organizational restructuring plan (the “2020 plan”), (b) the impact of certain non-recurring transaction costs in connection with the acquisition of Sequence (as defined below), and (c) the impact of the impairment charges for the Company's goodwill related to its Republic of Ireland and Northern Ireland reporting units and the impairment charge for the Company's franchise rights acquired related to its Northern Ireland unit of account; (iii) the fourth quarter of fiscal 2022 to exclude (a) the impact of impairment charges for the Company's franchise rights acquired related to its United States, Canada, United Kingdom and Australia units of account and an impairment charge for the Company's goodwill related to its Republic of Ireland reporting unit and (b) the net impact of (w) charges associated with the Company's 2023 plan, (x) charges associated with the Company's 2022 plan, (y) the reversal of certain of the charges associated with the Company's 2021 plan, and (z) the reversal of certain of the charges associated with the Company's 2020 plan; and (iv) the full year of fiscal 2022 to exclude (a) the impact of impairment charges for the Company's franchise rights acquired related to its United States, Canada, United Kingdom, New Zealand and Australia units of account and impairment charges for the Company's goodwill related to its Republic of Ireland reporting unit and its wholly-owned subsidiary Kurbo, Inc., and (b) the net impact of (w) charges associated with the 2023 plan, (x) charges associated with the 2022 plan, (y) charges associated with the 2021 plan or the reversal of certain of the charges associated with the 2021 plan, as applicable, and (z) the reversal of certain of the charges associated with the 2020 plan. We generally refer to such non-GAAP measures as follows: (i) with respect to the adjustments for the fourth quarter of fiscal 2023, as excluding or adjusting for the net impact of restructuring charges and the impact of franchise rights acquired and goodwill impairments; (ii) with respect to the adjustments for the full year of fiscal 2023, as excluding or adjusting for the net impact of restructuring charges, the impact of acquisition transaction costs, and the impact of franchise rights acquired and goodwill impairments; and (iii) with respect to the adjustments for the fourth quarter and full year of fiscal 2022, as excluding or adjusting for the impact of franchise rights acquired and goodwill impairments and the net impact of restructuring charges. The Company also presents in the attachments to this release the non-GAAP financial measures earnings before interest, taxes, depreciation, amortization and stock-based compensation (“EBITDAS”); earnings before interest, taxes, depreciation, amortization, stock-based compensation, franchise rights acquired and goodwill impairments, net restructuring charges, and certain non-recurring transaction costs in connection with the acquisition of Sequence (“Adjusted EBITDAS”); total debt less unamortized deferred financing costs, unamortized debt discount and cash on hand (i.e., net debt); and a net debt/Adjusted EBITDAS ratio. In addition, the Company presents certain of its financial results on a constant currency basis in addition to GAAP results. Constant currency information compares results between periods as if exchange rates had remained constant period-over-period. The Company calculates constant currency by calculating current-year results using prior-year foreign currency exchange rates. A reconciliation of the forward-looking full year EBITDAS outlook to net income cannot be provided without unreasonable effort because of the inherent difficulty of accurately forecasting the occurrence and financial impact of the various adjusting items necessary for such reconciliation that have not yet occurred, are out of our control, or cannot be reasonably predicted. For the same reasons, the Company is unable to assess the probable significance of the unavailable information, which could have a material impact on its future GAAP financial results.
Management believes these non-GAAP financial measures provide useful supplemental information for its and investors' evaluation of the Company's business performance and are useful for period-over-period comparisons of the performance of the Company's business. While management believes that these non-GAAP financial measures are useful in evaluating the Company's business, this information should be considered as supplemental in nature and should not be considered in isolation or as a substitute for the related financial information prepared in accordance with GAAP. In addition, these non-GAAP financial measures may not be the same as similarly titled measures reported by other companies. See "Reconciliation of Non-GAAP Financial Measures" attached to this release and reconciliations, if any, included elsewhere in this release for a reconciliation of the non-GAAP financial measures to the most directly comparable GAAP measures.
About WW International, Inc.
WeightWatchers is a human-centric technology company powered by our proven, science-based, clinically effective weight loss and weight management programs. For six decades, we have inspired millions of people to adopt healthy habits for real life. We combine technology and community to help members reach and sustain their goals on our programs. To learn more about the WeightWatchers approach to healthy living, please visit ww.com. For more information about our global business, visit our corporate website at corporate.ww.com.
This news release and any attachments include “forward-looking statements,” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including, in particular, any guidance and any statements about the Company’s plans, strategies, objectives, initiatives, roadmap and prospects. The Company generally uses the words “may,” “will,” “could,” “expect,” “anticipate,” “believe,” “estimate,” “plan,” “intend,” “aim” and similar expressions in this news release and any attachments to identify forward-looking statements. The Company bases these forward-looking statements on its current views with respect to future events and financial performance. Actual results could differ materially from those projected in the forward-looking statements. These forward-looking statements are subject to risks, uncertainties and assumptions, including, among other things: competition from other weight management and health and wellness industry participants or the development of more effective or more favorably perceived weight management methods; the Company's failure to continue to retain and grow its subscriber base; the Company’s ability to be a leader in the rapidly evolving and increasingly competitive clinical weight management and weight loss market; the Company's ability to continue to develop new, innovative services and products and enhance its existing services and products or the failure of its services, products or brands to continue to appeal to the market, or its ability to successfully expand into new channels of distribution or respond to consumer trends or sentiment; the ability to successfully implement strategic initiatives; the Company’s ability to evolve its community offerings to meet the evolving tastes and preferences of its members; the effectiveness and efficiency of the Company's advertising and marketing programs, including the strength of the Company's social media presence; the impact on the Company's reputation of actions taken by its franchisees, licensees, suppliers, affiliated provider entities, PCs’ healthcare professionals, and other partners, including as a result of its acquisition of Weekend Health, Inc., doing business as Sequence (“Sequence”) (the “Acquisition”); the recognition of asset impairment charges; the loss of key personnel, strategic partners or consultants or failure to effectively manage and motivate the Company's workforce; the Company’s ability to successfully make acquisitions or enter into collaborations or joint ventures, including its ability to successfully integrate, operate or realize the anticipated benefits of such businesses, including with respect to Sequence; uncertainties related to a downturn in general economic conditions or consumer confidence, including as a result of the existing inflationary environment, rising interest rates, the potential impact of political and social unrest and increased volatility in the credit and capital markets; the seasonal nature of the Company's business; the Company's failure to maintain effective internal control over financial reporting; the impact of events that impede accessing resources or discourage or impede people from gathering with others; the early termination by the Company of leases; the inability to renew certain of the Company's licenses, or the inability to do so on terms that are favorable to the Company; the impact of the Company's substantial amount of debt, debt service obligations and debt covenants, and its exposure to variable rate indebtedness; the ability to generate sufficient cash to service the Company's debt and satisfy its other liquidity requirements; uncertainties regarding the satisfactory operation of the Company's technology or systems; the impact of data security breaches and other malicious acts or privacy concerns, including the costs of compliance with evolving privacy laws and regulations; the Company’s ability to successfully integrate and use artificial intelligence in its business; the Company's ability to enforce its intellectual property rights both domestically and internationally, as well as the impact of its involvement in any claims related to intellectual property rights; risks and uncertainties associated with the Company's international operations, including regulatory, economic, political, social, intellectual property, and foreign currency risks, which risks may be exacerbated as a result of war and terrorism; the outcomes of litigation or regulatory actions; the impact of existing and future laws and regulations; risks related to the Acquisition, including risks that the Acquisition may not achieve its intended results; risks related to the Company's exposure to extensive and complex healthcare laws and regulations as a result of the Acquisition; and other risks and uncertainties, including those detailed from time to time in the Company's periodic reports filed with the United States Securities and Exchange Commission (the “SEC”) (which are available on the SEC’s EDGAR database at www.sec.gov and via the Company’s website at corporate.ww.com). You should not put undue reliance on any forward-looking statements. You should understand that many important factors, including those discussed herein, could cause the Company’s results to differ materially from those expressed or suggested in any forward-looking statement. Except as required by law, the Company does not undertake any obligation to update or revise these forward-looking statements to reflect new information or events or circumstances that occur after the date of this news release or to reflect the occurrence of unanticipated events or otherwise. Readers are advised to review the Company’s filings with the SEC (which are available on the SEC’s EDGAR database at www.sec.gov and via the Company’s website at corporate.ww.com).
WW INTERNATIONAL, INC. AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS AT (IN THOUSANDS) UNAUDITED December 30, December 31, 2023 2022 ASSETS CURRENT ASSETS Cash and cash equivalents $109,366 $178,326 Receivables (net of allowances: December 30, 2023 - $1,041 and December 31, 2022 - $976) 14,938 24,273 Inventories 68 20,528 Prepaid income taxes 25,370 19,447 Prepaid marketing and advertising 10,149 7,927 Prepaid expenses and other current assets 19,583 30,830 TOTAL CURRENT ASSETS 179,474 281,331 Property and equipment, net 19,741 28,229 Operating lease assets 52,272 75,696 Franchise rights acquired 386,526 386,745 Goodwill 243,441 155,998 Other intangible assets, net 63,208 63,306 Deferred income taxes 19,683 22,246 Other noncurrent assets 17,685 14,879 TOTAL ASSETS $982,030 $1,028,430 LIABILITIES AND TOTAL DEFICIT CURRENT LIABILITIES Portion of operating lease liabilities due within one year $9,613 $17,955 Accounts payable 18,507 18,890 Salaries and wages payable 79,096 72,577 Accrued marketing and advertising 18,215 17,927 Accrued interest 5,346 5,289 Deferred acquisition payable 16,500 1,166 Other accrued liabilities 22,610 28,952 Income taxes payable 1,609 1,646 Deferred revenue 33,966 32,156 TOTAL CURRENT LIABILITIES 205,462 196,558 Long-term debt, net 1,426,464 1,422,284 Long-term operating lease liabilities 53,461 68,099 Deferred income taxes 41,994 25,084 (1)Other 15,743 2,185 TOTAL LIABILITIES 1,743,124 1,714,210 (1)TOTAL DEFICIT Common stock, $0 par value; 1,000,000 shares authorized; 130,048 shares issued at December 30, 2023 and 122,052 shares issued at December 31, 2022 0 0 Treasury stock, at cost, 50,859 shares at December 30, 2023 and 51,496 shares at December 31, 2022 (3,064,628) (3,097,304) Retained earnings 2,314,834 2,416,994 (1) Accumulated other comprehensive loss (11,300) (5,470) TOTAL DEFICIT (761,094) (685,780)(1) TOTAL LIABILITIES AND TOTAL DEFICIT $982,030 $1,028,430 (1) Certain amounts have been revised at December 31, 2022 to correct immaterial misstatements related to certain income tax matters, which will be more fully described in the Company's Form 10-K filing for the fiscal year ended December 30, 2023.
WW INTERNATIONAL, INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS (IN THOUSANDS, EXCEPT PER SHARE AMOUNTS) UNAUDITED Three Months Ended December 30, December 31, 2023 2022 Subscription revenues, net (1) $196,087 $200,932 Product sales and other, net (2) 9,868 21,970 (4) Revenues, net 205,955 222,902 (4)Cost of subscription revenues (3) 67,707 77,817 Cost of product sales and other 13,391 19,117 Cost of revenues 81,098 96,934 Gross profit 124,857 125,968 (4)Marketing expenses 50,920 49,660 Selling, general and administrative expenses 76,312 70,520 Franchise rights acquired and goodwill impairments 3,633 57,566 Operating loss (6,008) (51,778)(4)Interest expense 24,464 22,304 Other expense (income), net 107 (1,611) Loss before income taxes (30,579) (72,471)(4)Provision for (benefit from) income taxes 57,556 (36,690)(4) Net loss $(88,135) $(35,781)(4) Net loss per share Basic $(1.11) $(0.51)(4) Diluted $(1.11) $(0.51)(4) Weighted average common shares outstanding Basic 79,125 70,509 Diluted 79,125 70,509 Note: Totals may not sum due to rounding. (1) Consists of net “Digital Subscription Revenues”, net “Workshops + Digital Fees” and net “Clinical Subscription Revenues”. “Digital Subscription Revenues” consist of the fees associated with subscriptions for the Company’s Digital offerings, which formerly included Personal Coaching + Digital and Digital 360 (as applicable). “Workshops + Digital Fees” consist of the fees associated with the Company's subscription plans for combined workshops and digital offerings and other payment arrangements for access to workshops. “Clinical Subscription Revenues” consist of the fees associated with subscriptions for the Company’s Clinical offerings. (2) Consists of sales of consumer products via e-commerce, in studios and through the Company's trusted partners, revenues from licensing and publishing, other revenues, and franchise fees with respect to commitment plans and royalties. (3) Consists of cost of revenues and operating expenses for the Company's Digital, Workshops + Digital and Clinical services. (4) Certain amounts have been revised for the three months ended December 31, 2022 to correct immaterial misstatements related to certain income tax and other matters, which will be more fully described in the Company's Form 10-K filing for the fiscal year ended December 30, 2023.
WW INTERNATIONAL, INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS (IN THOUSANDS, EXCEPT PER SHARE AMOUNTS) UNAUDITED Twelve Months Ended December 30, December 31, 2023 2022 Subscription revenues, net (1) $822,755 $919,055 Product sales and other, net (2) 66,796 120,780 (4) Revenues, net 889,551 1,039,835 (4)Cost of subscription revenues (3) 301,062 321,528 Cost of product sales and other 59,186 96,928 Cost of revenues 360,248 418,456 Gross profit 529,303 621,379 (4)Marketing expenses 238,387 244,783 Selling, general and administrative expenses 264,950 263,840 Franchise rights acquired and goodwill impairments 3,633 396,727 Operating income (loss) 22,333 (283,971)(4)Interest expense 95,893 81,141 Other expense, net 72 1,691 Loss before income taxes (73,632) (366,803)(4)Provision for (benefit from) income taxes 38,623 (109,935)(4) Net loss $(112,255) $(256,868)(4) Net loss per share Basic $(1.46) $(3.65)(4) Diluted $(1.46) $(3.65)(4) Weighted average common shares outstanding Basic 76,677 70,321 Diluted 76,677 70,321 Note: Totals may not sum due to rounding. (1) Consists of net “Digital Subscription Revenues”, net “Workshops + Digital Fees” and net “Clinical Subscription Revenues”. “Digital Subscription Revenues” consist of the fees associated with subscriptions for the Company’s Digital offerings, which formerly included Personal Coaching + Digital and Digital 360 (as applicable). “Workshops + Digital Fees” consist of the fees associated with the Company's subscription plans for combined workshops and digital offerings and other payment arrangements for access to workshops. “Clinical Subscription Revenues” consist of the fees associated with subscriptions for the Company’s Clinical offerings. (2) Consists of sales of consumer products via e-commerce, in studios and through the Company's trusted partners, revenues from licensing and publishing, other revenues, and franchise fees with respect to commitment plans and royalties. (3) Consists of cost of revenues and operating expenses for the Company's Digital, Workshops + Digital and Clinical services. (4) Certain amounts have been revised for the twelve months ended December 31, 2022 to correct immaterial misstatements related to certain income tax and other matters, which will be more fully described in the Company's Form 10-K filing for the fiscal year ended December 30, 2023.
WW INTERNATIONAL, INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF CASH FLOWS (IN THOUSANDS) UNAUDITED Twelve Months Ended December 30, December 31, 2023 2022 Operating activities: Net loss $(112,255) $(256,868)(1) Adjustments to reconcile net loss to cash provided by operating activities: Depreciation and amortization 52,471 43,801 Amortization of deferred financing costs and debt discount 5,018 5,018 Impairment of franchise rights acquired and goodwill 3,633 396,727 Impairment of intangible and long-lived assets 1,112 3,455 Share-based compensation expense 15,185 12,957 Deferred tax provision (benefit) 19,821 (145,829)(1) Allowance for doubtful accounts 1,306 (460) Reserve for inventory obsolescence 7,350 6,796 Foreign currency exchange rate loss 263 2,374 Changes in cash due to: Receivables 17,112 (7,558) Inventories 14,018 3,733 Prepaid expenses (4,133) 8,878 (1) Accounts payable (54) (2,691) Accrued liabilities (11,625) 20,925 (1) Deferred revenue 1,273 (11,733) Other long term assets and liabilities, net (3,598) (2,291) Income taxes (211) (588) Cash provided by operating activities 6,686 76,646 Investing activities: Capital expenditures (2,485) (2,065) Capitalized software and website development expenditures (33,816) (36,187) Cash paid for acquisitions, net of cash acquired (38,362) (4,350) Other items, net (33) (42) Cash used for investing activities (74,696) (42,644) Financing activities: Taxes paid related to net share settlement of equity awards (2,241) (2,197) Proceeds from stock options exercised 718 — Cash paid for acquisitions (1,178) (2,413) Other items, net (48) (112) Cash used for financing activities (2,749) (4,722) Effect of exchange rate changes on cash and cash equivalents 1,799 (4,748) Net (decrease) increase in cash and cash equivalents (68,960) 24,532 Cash and cash equivalents, beginning of period 178,326 153,794 Cash and cash equivalents, end of period $109,366 $178,326 (1) Certain amounts have been revised for the twelve months ended December 31, 2022 to correct immaterial misstatements related to certain income tax and other matters, which will be more fully described in the Company's Form 10-K filing for the fiscal year ended December 30, 2023.
WW INTERNATIONAL, INC. AND SUBSIDIARIES OPERATIONAL STATISTICS (IN THOUSANDS, EXCEPT PERCENTAGES) UNAUDITED Three Months Ended December 30, December 31, Variance 2023 2022 Digital Paid Weeks (1) North America26,124 23,714 10.2% International14,886 14,043 6.0% Total Digital Paid Weeks41,010 37,757 8.6% Workshops + Digital Paid Weeks (1) North America6,483 7,178 (9.7%) International2,220 2,407 (7.8%) Total Workshops + Digital Paid Weeks8,703 9,585 (9.2%) Clinical Paid Weeks (1) North America719 — N/A International— — — Total Clinical Paid Weeks719 — N/A Total Paid Weeks (1) North America33,327 30,892 7.9% International17,106 16,449 4.0% Total Paid Weeks50,432 47,342 6.5% End of Period Digital Subscribers (2) North America1,948 1,802 8.1% International1,131 1,033 9.5% Total End of Period Digital Subscribers3,079 2,836 8.6% End of Period Workshops + Digital Subscribers (2) North America484 534 (9.4%) International167 176 (4.9%) Total End of Period Workshops + Digital Subscribers652 711 (8.3%) End of Period Clinical Subscribers (2) North America67 — N/A International— — — Total End of Period Clinical Subscribers67 — N/A Total End of Period Subscribers (2) North America2,499 2,337 6.9% International1,299 1,209 7.4% Total End of Period Subscribers3,798 3,546 7.1% Note: Totals may not sum due to rounding. (1) The “Paid Weeks” metric reports paid weeks by WW customers in Company-owned operations for a given period as follows: (i) “Digital Paid Weeks” is the total paid subscription weeks for the Company’s digital subscription products, which formerly included Personal Coaching + Digital and Digital 360 (as applicable); (ii) “Workshops + Digital Paid Weeks” is the sum of total paid commitment plan weeks which include workshops and digital offerings; (iii) “Clinical Paid Weeks” is the total paid subscription weeks for the Company’s Clinical subscription products; and (iv) “Total Paid Weeks” is the sum of Digital Paid Weeks, Workshops + Digital Paid Weeks and Clinical Paid Weeks. (2) The “End of Period Subscribers” metric reports WW subscribers in Company-owned operations at a given period end as follows: (i) “End of Period Digital Subscribers” is the total number of Digital, including former Personal Coaching + Digital and Digital 360 (as applicable), subscribers; (ii) “End of Period Workshops + Digital Subscribers” is the total number of commitment plan subscribers that have access to combined workshops and digital offerings; (iii) “End of Period Clinical Subscribers” is the total number of Clinical subscribers; and (iv) “End of Period Subscribers” is the sum of End of Period Digital Subscribers, End of Period Workshops + Digital Subscribers and End of Period Clinical Subscribers.
WW INTERNATIONAL, INC. AND SUBSIDIARIES OPERATIONAL STATISTICS (IN THOUSANDS, EXCEPT PERCENTAGES) UNAUDITED Twelve Months Ended December 30, December 31, Variance 2023 2022 Digital Paid Weeks (1) North America107,516 111,457 (3.5%) International60,351 64,355 (6.2%) Total Digital Paid Weeks167,868 175,812 (4.5%) Workshops + Digital Paid Weeks (1) North America28,397 29,902 (5.0%) International9,345 9,954 (6.1%) Total Workshops + Digital Paid Weeks37,742 39,856 (5.3%) Clinical Paid Weeks (1) North America1,608 — N/A International— — — Total Clinical Paid Weeks1,608 — N/A Total Paid Weeks (1) North America137,522 141,359 (2.7%) International69,697 74,309 (6.2%) Total Paid Weeks207,218 215,668 (3.9%) End of Period Digital Subscribers (2) North America1,948 1,802 8.1% International1,131 1,033 9.5% Total End of Period Digital Subscribers3,079 2,836 8.6% End of Period Workshops + Digital Subscribers (2) North America484 534 (9.4%) International167 176 (4.9%) Total End of Period Workshops + Digital Subscribers652 711 (8.3%) End of Period Clinical Subscribers (2) North America67 — N/A International— — — Total End of Period Clinical Subscribers67 — N/A Total End of Period Subscribers (2) North America2,499 2,337 6.9% International1,299 1,209 7.4% Total End of Period Subscribers3,798 3,546 7.1% Note: Totals may not sum due to rounding. (1) The “Paid Weeks” metric reports paid weeks by WW customers in Company-owned operations for a given period as follows: (i) “Digital Paid Weeks” is the total paid subscription weeks for the Company’s digital subscription products, which formerly included Personal Coaching + Digital and Digital 360 (as applicable); (ii) “Workshops + Digital Paid Weeks” is the sum of total paid commitment plan weeks which include workshops and digital offerings; (iii) “Clinical Paid Weeks” is the total paid subscription weeks for the Company’s Clinical subscription products; and (iv) “Total Paid Weeks” is the sum of Digital Paid Weeks, Workshops + Digital Paid Weeks and Clinical Paid Weeks. (2) The “End of Period Subscribers” metric reports WW subscribers in Company-owned operations at a given period end as follows: (i) “End of Period Digital Subscribers” is the total number of Digital, including former Personal Coaching + Digital and Digital 360 (as applicable), subscribers; (ii) “End of Period Workshops + Digital Subscribers” is the total number of commitment plan subscribers that have access to combined workshops and digital offerings; (iii) “End of Period Clinical Subscribers” is the total number of Clinical subscribers; and (iv) “End of Period Subscribers” is the sum of End of Period Digital Subscribers, End of Period Workshops + Digital Subscribers and End of Period Clinical Subscribers.
WW INTERNATIONAL, INC. AND SUBSIDIARIESRECONCILIATION OF NON-GAAP FINANCIAL MEASURES(IN THOUSANDS, EXCEPT PERCENTAGES)UNAUDITED Q4 2023 Variance 2023 Constant Q4 2023 Q4 2022 2023 Currency Currency Constant vs vs GAAP Adjustment Currency GAAP 2022 2022 Selected Financial Data Consolidated Company Revenues$205,955 $(2,434) $203,521 $222,902(6)(7.6%) (8.7%) Consolidated Digital Subscription Revenues (1)$133,459 $(1,984) $131,475 $141,085 (5.4%) (6.8%) Consolidated Workshops + Digital Fees (2)$49,666 $(395) $49,271 $59,847 (17.0%) (17.7%) Consolidated Clinical Subscription Revenues (3)$12,962 $— $12,962 $— N/A N/A Consolidated Subscription Revenues (4)$196,087 $(2,379) $193,708 $200,932 (2.4%) (3.6%) Consolidated Product Sales and Other (5)$9,868 $(55) $9,813 $21,970(6)(55.1%) (55.3%) North America Digital Subscription Revenues (1)$88,349 $16 $88,365 $93,659 (5.7%) (5.7%) Workshops + Digital Fees (2)$40,415 $8 $40,423 $48,558 (16.8%) (16.8%) Clinical Subscription Revenues (3)$12,962 $— $12,962 $— N/A N/A Subscription Revenues (4)$141,726 $23 $141,749 $142,217 (0.3%) (0.3%) Product Sales and Other (5)$8,570 $1 $8,571 $15,616(6)(45.1%) (45.1%) Total Revenues$150,296 $25 $150,321 $157,833(6)(4.8%) (4.8%) International Digital Subscription Revenues (1)$45,110 $(1,999) $43,111 $47,426 (4.9%) (9.1%) Workshops + Digital Fees (2)$9,251 $(403) $8,848 $11,289 (18.1%) (21.6%) Clinical Subscription Revenues (3)$— $— $— $— N/A N/A Subscription Revenues (4)$54,361 $(2,402) $51,959 $58,715 (7.4%) (11.5%) Product Sales and Other (5)$1,298 $(56) $1,242 $6,354 (79.6%) (80.5%) Total Revenues$55,659 $(2,459) $53,200 $65,069 (14.5%) (18.2%) Note: Totals may not sum due to rounding. (1) “Digital Subscription Revenues” consist of the fees associated with subscriptions for the Company’s Digital offerings, which formerly included Personal Coaching + Digital and Digital 360 (as applicable). (2) “Workshops + Digital Fees” consist of the fees associated with the Company's subscription plans for combined workshops and digital offerings and other payment arrangements for access to workshops. (3) “Clinical Subscription Revenues” consist of the fees associated with subscriptions for the Company’s Clinical offerings. (4) “Subscription Revenues” equal “Digital Subscription Revenues” plus “Workshops + Digital Fees” plus “Clinical Subscription Revenues”. (5) “Product Sales and Other” are sales of consumer products via e-commerce, in studios and through the Company's trusted partners, revenues from licensing and publishing, other revenues, and, in the case of the consolidated financial results and North America reportable segment, franchise fees with respect to commitment plans and royalties. (6) Certain amounts have been revised for Q4 2022 to correct immaterial misstatements related to certain matters, which will be more fully described in the Company's Form 10-K filing for the fiscal year ended December 30, 2023.
WW INTERNATIONAL, INC. AND SUBSIDIARIESRECONCILIATION OF NON-GAAP FINANCIAL MEASURES(IN THOUSANDS, EXCEPT PERCENTAGES)UNAUDITED Full Year 2023 Variance 2023 Constant Full Year 2023 Full Year 20222023 Currency Currency Constant vs vs GAAP Adjustment Currency GAAP 2022 2022 Selected Financial Data Consolidated Company Revenues$889,551 $(740) $888,811 $1,039,835(6)(14.5%) (14.5%) Consolidated Digital Subscription Revenues (1)$571,074 $(1,376) $569,698 $662,668 (13.8%) (14.0%) Consolidated Workshops + Digital Fees (2)$221,139 $207 $221,346 $256,387 (13.7%) (13.7%) Consolidated Clinical Subscription Revenues (3)$30,542 $— $30,542 $— N/A N/A Consolidated Subscription Revenues (4)$822,755 $(1,169) $821,586 $919,055 (10.5%) (10.6%) Consolidated Product Sales and Other (5)$66,796 $429 $67,225 $120,780(6)(44.7%) (44.3%) North America Digital Subscription Revenues (1)$374,004 $894 $374,898 $436,148 (14.2%) (14.0%) Workshops + Digital Fees (2)$179,054 $334 $179,388 $204,115 (12.3%) (12.1%) Clinical Subscription Revenues (3)$30,542 $— $30,542 $— N/A N/A Subscription Revenues (4)$583,600 $1,228 $584,828 $640,263 (8.8%) (8.7%) Product Sales and Other (5)$54,596 $117 $54,713 $87,095(6)(37.3%) (37.2%) Total Revenues$638,196 $1,345 $639,541 $727,358(6)(12.3%) (12.1%) International Digital Subscription Revenues (1)$197,070 $(2,270) $194,800 $226,520 (13.0%) (14.0%) Workshops + Digital Fees (2)$42,085 $(127) $41,958 $52,272 (19.5%) (19.7%) Clinical Subscription Revenues (3)$— $— $— $— N/A N/A Subscription Revenues (4)$239,155 $(2,397) $236,758 $278,792 (14.2%) (15.1%) Product Sales and Other (5)$12,200 $312 $12,512 $33,685 (63.8%) (62.9%) Total Revenues$251,355 $(2,085) $249,270 $312,477 (19.6%) (20.2%) Note: Totals may not sum due to rounding. (1) “Digital Subscription Revenues” consist of the fees associated with subscriptions for the Company’s Digital offerings, which formerly included Personal Coaching + Digital and Digital 360 (as applicable). (2) “Workshops + Digital Fees” consist of the fees associated with the Company's subscription plans for combined workshops and digital offerings and other payment arrangements for access to workshops. (3) “Clinical Subscription Revenues” consist of the fees associated with subscriptions for the Company’s Clinical offerings. (4) “Subscription Revenues” equal “Digital Subscription Revenues” plus “Workshops + Digital Fees” plus “Clinical Subscription Revenues”. (5) “Product Sales and Other” are sales of consumer products via e-commerce, in studios and through the Company's trusted partners, revenues from licensing and publishing, other revenues, and, in the case of the consolidated financial results and North America reportable segment, franchise fees with respect to commitment plans and royalties. (6) Certain amounts have been revised for full year 2022 to correct immaterial misstatements related to certain matters, which will be more fully described in the Company's Form 10-K filing for the fiscal year ended December 30, 2023.
WW INTERNATIONAL, INC. AND SUBSIDIARIES RECONCILIATION OF NON-GAAP FINANCIAL MEASURES (IN THOUSANDS, EXCEPT PERCENTAGES) UNAUDITED Q4 2023 Variance 2023 Constant Currency 2023 2023 Q4 2023 Q4 2022 Adjusted Adjusted Adjusted 2023 vs 2023 vs Currency Constant Constant vs 2022 vs 2022 GAAP Adjustment Adjusted AdjustmentCurrency Currency GAAP Adjustment Adjusted 2022 Adjusted 2022 Adjusted Selected Financial Data Gross Profit$124,857 $1,512(1)$126,369 $(1,922) $122,935 $124,447 $125,968(5)$3,128(6)$129,096(5)(0.9%) (2.1%) (2.4%) (3.6%) Gross Margin60.6% 61.4% 60.4% 61.1% 56.5%(5) 57.9%(5) Selling, General and Administrative Expenses $76,312 $(22,117)(2)$54,195 $(402) $75,910 $53,793 $70,520 $(14,223)(7)$56,297 8.2% (3.7%) 7.6% (4.4%) Operating (Loss) Income$(6,008) $27,262(3)$21,254 $(857) $(6,865) $20,276(4)$(51,778)(5)$74,918(8)$23,140(5)(88.4%) (8.1%) (86.7%) (12.4%) Operating Income (Loss) Margin(2.9%) 10.3% (3.4%) 10.0% (23.2%)(5) 10.4%(5) Note: Totals may not sum due to rounding. (1) Excludes the net impact of $1,247 of charges associated with the Company's previously disclosed 2023 restructuring plan and $265 of charges associated with the Company's previously disclosed 2022 restructuring plan. (2) Excludes the net impact of $21,893 of charges associated with the Company's previously disclosed 2023 restructuring plan and $224 of charges associated with the Company's previously disclosed 2022 restructuring plan. (3) Excludes (i) the net impact of (y) $1,247 of charges and $21,893 of charges associated with the Company's previously disclosed 2023 restructuring plan recorded to cost of subscription revenues and selling, general and administrative expenses, respectively, and (z) $265 of charges and $224 of charges associated with the Company's previously disclosed 2022 restructuring plan recorded to cost of subscription revenues and selling, general and administrative expenses, respectively, and (ii) the impact of impairment charges of the Company's goodwill related to its Republic of Ireland and Northern Ireland reporting units of $2,383 and $1,203, respectively, and the impairment charge of the Company's franchise rights acquired related to its Northern Ireland unit of account of $47. (4) Includes $121 of currency adjustment associated with the impairment charges of the Company's goodwill related to its Republic of Ireland and Northern Ireland reporting units of $2,383 and $1,203, respectively, and the impairment charge of the Company's franchise rights acquired related to its Northern Ireland unit of account of $47. (5) Certain amounts have been revised for Q4 2022 to correct immaterial misstatements related to certain matters, which will be more fully described in the Company's Form 10-K filing for the fiscal year ended December 30, 2023. (6) Excludes the net impact of $1,798 of charges associated with the Company's previously disclosed 2023 restructuring plan, $2,075 of charges associated with the Company's previously disclosed 2022 restructuring plan, the reversal of $132 of charges associated with the Company's previously disclosed 2021 organizational restructuring plan and the reversal of $613 of charges associated with the Company's previously disclosed 2020 organizational restructuring plan. (7) Excludes the net impact of $11,810 of charges associated with the Company's previously disclosed 2023 restructuring plan, $2,432 of charges associated with the Company's previously disclosed 2022 restructuring plan, the reversal of $10 of charges associated with the Company's previously disclosed 2021 organizational restructuring plan and the reversal of $8 of charges associated with the Company's previously disclosed 2020 organizational restructuring plan. (8) Excludes (i) the impact of impairment charges of the Company's franchise rights acquired of $25,739, $19,657, $8,275 and $1,872 related to its United States, Canada, United Kingdom and Australia units of account, respectively, and an impairment charge of the Company's goodwill related to its Republic of Ireland reporting unit of $2,023 and (ii) the net impact of (w) $1,798 of charges and $11,810 of charges associated with the Company's previously disclosed 2023 restructuring plan recorded to cost of subscription revenues and selling, general and administrative expenses, respectively, (x) $2,075 of charges and $2,432 of charges associated with the Company's previously disclosed 2022 restructuring plan recorded to cost of subscription revenues and selling, general and administrative expenses, respectively, (y) the reversal of $132 of charges and the reversal of $10 of charges associated with the Company's previously disclosed 2021 organizational restructuring plan recorded to cost of subscription revenues and selling, general and administrative expenses, respectively, and (z) the reversal of $613 of charges and the reversal of $8 of charges associated with the Company's previously disclosed 2020 organizational restructuring plan recorded to cost of subscription revenues and selling, general and administrative expenses, respectively.
WW INTERNATIONAL, INC. AND SUBSIDIARIES RECONCILIATION OF NON-GAAP FINANCIAL MEASURES (IN THOUSANDS, EXCEPT PERCENTAGES) UNAUDITED Full Year 2023 Variance 2023 Constant Currency 2023 2023 Full Year 2023 Full Year 2022 Adjusted Adjusted Adjusted 2023 vs 2023 vs Currency Constant Constant vs 2022 vs 2022 GAAP Adjustment Adjusted AdjustmentCurrency Currency GAAP Adjustment Adjusted 2022 Adjusted 2022 Adjusted Selected Financial Data Gross Profit$529,303 $21,187 (1)$550,490 $(1,367) $527,936 $549,123 $621,379 (5)$6,981 (6)$628,360 (5)(14.8%) (12.4%) (15.0%) (12.6%) Gross Margin 59.5% 61.9% 59.4% 61.8% 59.8% 60.4% (5) Selling, General and Administrative Expenses $264,950 $(42,332)(2)$222,618 $(26) $264,924 $222,593 $263,840 $(32,730)(7)$231,110 0.4% (3.7%) 0.4% (3.7%) Operating Income (Loss)$22,333 $67,152 (3)$89,485 $(1,999) $20,334 $87,365 (4)$(283,971)(5)$436,438 (8)$152,467 (5)(107.9%) (41.3%) (107.2%) (42.7%) Operating Income (Loss) Margin 2.5% 10.1% 2.3% 9.8% (27.3%) (5) 14.7% Note: Totals may not sum due to rounding. (1) Excludes the net impact of $21,116 of charges associated with the Company's previously disclosed 2023 restructuring plan, the reversal of $4 of charges associated with the Company's previously disclosed 2022 restructuring plan, $96 of charges associated with the Company's previously disclosed 2021 organizational restructuring plan and the reversal of $21 of charges associated with the Company's previously disclosed 2020 organizational restructuring plan. (2) Excludes (i) the net impact of $32,627 of charges associated with the Company's previously disclosed 2023 restructuring plan, $1,139 of charges associated with the Company's previously disclosed 2022 restructuring plan and the reversal of $39 of charges associated with the Company's previously disclosed 2021 organizational restructuring plan, and (ii) the impact of $8,605 of acquisition transaction costs. (3) Excludes (i) the net impact of (w) $21,116 of charges and $32,627 of charges associated with the Company's previously disclosed 2023 restructuring plan recorded to cost of subscription revenues and selling, general and administrative expenses, respectively, (x) the reversal of $4 of charges and $1,139 of charges associated with the Company's previously disclosed 2022 restructuring plan recorded to cost of subscription revenues and selling, general and administrative expenses, respectively, (y) $96 of charges and the reversal of $39 of charges associated with the Company's previously disclosed 2021 organizational restructuring plan recorded to cost of subscription revenues and selling, general and administrative expenses, respectively, and (z) the reversal of $21 of charges associated with the Company's previously disclosed 2020 organizational restructuring plan recorded to cost of subscription revenues, (ii) the impact of $8,605 of acquisition transaction costs recorded to selling, general and administrative expenses, and (iii) the impact of impairment charges of the Company's goodwill related to its Republic of Ireland and Northern Ireland reporting units of $2,383 and $1,203, respectively, and the impairment charge of the Company's franchise rights acquired related to its Northern Ireland unit of account of $47. (4) Includes $121 of currency adjustment associated with the impairment charges of the Company's goodwill related to its Republic of Ireland and Northern Ireland reporting units of $2,383 and $1,203, respectively, and the impairment charge of the Company's franchise rights acquired related to its Northern Ireland unit of account of $47. (5) Certain amounts have been revised for full year 2022 to correct immaterial misstatements related to certain matters, which will be more fully described in the Company's Form 10-K filing for the fiscal year ended December 30, 2023. (6) Excludes the net impact of $1,798 of charges associated with the Company's previously disclosed 2023 restructuring plan, $6,476 of charges associated with the Company's previously disclosed 2022 restructuring plan, the reversal of $564 of charges associated with the Company's previously disclosed 2021 organizational restructuring plan and the reversal of $729 of charges associated with the Company's previously disclosed 2020 organizational restructuring plan. (7) Excludes the net impact of $11,810 of charges associated with the Company's previously disclosed 2023 restructuring plan, $20,705 of charges associated with the Company's previously disclosed 2022 restructuring plan, $223 of charges associated with the Company's previously disclosed 2021 organizational restructuring plan and the reversal of $8 of charges associated with the Company's previously disclosed 2020 organizational restructuring plan. (8) Excludes (i) the impact of impairment charges of the Company's franchise rights acquired of $324,030, $57,454, $8,275, $1,972 and $1,872 related to its United States, Canada, United Kingdom, New Zealand and Australia units of account, respectively, and impairment charges of the Company's goodwill related to its Republic of Ireland reporting unit and its Kurbo operations of $2,023 and $1,101, respectively, and (ii) the net impact of (v) $1,798 of charges and $11,810 of charges associated with the Company's previously disclosed 2023 restructuring plan recorded to cost of subscription revenues and selling, general and administrative expenses, respectively, (w) $6,476 of charges and $20,705 of charges associated with the Company's previously disclosed 2022 restructuring plan recorded to cost of subscription revenues and selling, general and administrative expenses, respectively, (x) the reversal of $564 of charges associated with the Company's previously disclosed 2021 organizational restructuring plan recorded to cost of subscription revenues, (y) $223 of charges associated with the Company's previously disclosed 2021 organizational restructuring plan recorded to selling, general and administrative expenses and (z) the reversal of $729 of charges and the reversal of $8 of charges associated with the Company's previously disclosed 2020 organizational restructuring plan recorded to cost of subscription revenues and selling, general and administrative expenses, respectively.
WW INTERNATIONAL, INC. AND SUBSIDIARIES RECONCILIATION OF NON-GAAP FINANCIAL MEASURES (IN THOUSANDS) UNAUDITED Three Months Ended Twelve Months Ended December 30, December 31, December 30, December 31, 2023 2022 2023 2022 Net Loss $(88,135) $(35,781)(1)$(112,255) $(256,868)(1)Interest 24,464 22,304 95,893 81,141 Taxes 57,556 (36,690)(1)38,623 (109,935)(1)Depreciation and Amortization 10,007 10,407 45,640 42,348 Stock-based Compensation 2,346 2,590 11,303 12,952 EBITDAS $6,238 $(37,170)(1)$79,204 $(230,362)(1) 2023 Plan Restructuring Charges (2) 23,140 13,608 53,743 13,608 2022 Plan Restructuring Charges (3) 489 4,507 1,135 27,181 2021 Plan Restructuring Charges (4) — (142) 57 (341) 2020 Plan Restructuring Charges (5) — (621) (21) (737) Acquisition Transaction Costs (6) — — 8,605 — Franchise Rights Acquired and Goodwill Impairments 3,633(7)57,566(8)3,633(7)396,727(9) Adjusted EBITDAS $33,500 $37,748(1)$146,356 $206,076(1) Note: Totals may not sum due to rounding. (1) Certain amounts have been revised for the three and twelve months ended December 31, 2022 to correct immaterial misstatements related to certain income tax and other matters, which will be more fully described in the Company's Form 10-K filing for the fiscal year ended December 30, 2023. (2) Charges associated with the Company's previously disclosed 2023 restructuring plan. (3) Charges associated with the Company's previously disclosed 2022 restructuring plan. (4) The reversal of charges or charges, as applicable, associated with the Company's previously disclosed 2021 organizational restructuring plan. (5) The reversal of charges associated with the Company's previously disclosed 2020 organizational restructuring plan. (6) Certain non-recurring transaction costs in connection with the Company's acquisition of Sequence. (7) Impairment charges of the Company's goodwill of $2,383 and $1,203 related to its Republic of Ireland and Northern Ireland reporting units, respectively, and the impairment charge of the Company's franchise rights acquired of $47 related to its Northern Ireland unit of account. (8) Impairment charges of the Company's franchise rights acquired of $25,739, $19,657, $8,275 and $1,872 related to its United States, Canada, United Kingdom and Australia units of account, respectively, and an impairment charge of the Company's goodwill related to its Republic of Ireland reporting unit of $2,023. (9) Impairment charges of the Company's franchise rights acquired of $324,030, $57,454, $8,275, $1,972 and $1,872 related to its United States, Canada, United Kingdom, New Zealand and Australia units of account, respectively, and impairment charges of the Company's goodwill related to its Republic of Ireland reporting unit and Kurbo operations of $2,023 and $1,101, respectively.
WW INTERNATIONAL, INC. AND SUBSIDIARIES RECONCILIATION OF NON-GAAP FINANCIAL MEASURES (IN THOUSANDS, EXCEPT RATIOS) UNAUDITED Trailing Twelve Q1 2023 Q2 2023 Q3 2023 Q4 2023 Months Net Debt to Adjusted EBITDAS Net (Loss) Income$(118,679)$50,828 $43,731 $(88,135) $(112,255) Interest 22,846 24,075 24,508 24,464 95,893 Taxes 67,580 (48,066) (38,447) 57,556 38,623 Depreciation and Amortization 10,273 11,932 13,428 10,007 45,640 Stock-based Compensation 2,669 3,063 3,225 2,346 11,303 EBITDAS$(15,311) $41,832 $46,445 $6,238 $79,204 2023 Plan Restructuring Charges (1) 22,632 1,784 6,187 23,140 53,743 2022 Plan Restructuring Charges (2) 40 818 (212) 489 1,135 2021 Plan Restructuring Charges (3) (7) 64 — — 57 2020 Plan Restructuring Charges (4) (5) (16) — — (21) Acquisition Transaction Costs (5) 3,719 4,886 — — 8,605 Franchise Rights Acquired and Goodwill Impairments (6) — — — 3,633 3,633 Adjusted EBITDAS$11,068 $49,368 $52,420 $33,500 $146,356 Total Debt $1,426,464 Less: Cash 109,366 Net Debt $1,317,098 Total Debt to Net Loss (12.7)X Net Debt to Adjusted EBITDAS 9.0 X Note: Totals may not sum due to rounding. (1) Charges associated with the Company's previously disclosed 2023 restructuring plan. (2) Charges or the reversal of charges, as applicable, associated with the Company's previously disclosed 2022 restructuring plan. (3) The reversal of charges or charges, as applicable, associated with the Company's previously disclosed 2021 organizational restructuring plan. (4) The reversal of charges associated with the Company's previously disclosed 2020 organizational restructuring plan. (5) Certain non-recurring transaction costs in connection with the Company's acquisition of Sequence, which includes $3,719 recast for Q1 2023. (6) Impairment charges of the Company's goodwill of $2,383 and $1,203 related to its Republic of Ireland and Northern Ireland reporting units, respectively, and the impairment charge of the Company's franchise rights acquired of $47 related to its Northern Ireland unit of account.
For more information, contact:
Investors:
Corey Kinger
corey.kinger@ww.com
Media:
Kelsey Merkel
kelsey.merkel@ww.com
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-Targets
-Drugs
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.